Dr. Tracy R. Klein, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 421
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
KS license 04-28967
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Via Christi Hospitals Wichita, Inc. Wichita, KS
- Wesley Medical Center Wichita, KS
- Rock Regional Hospital, LLC Derby, KS
Medical groups
- Select Rehabilitation, LLC (2,046 clinicians)
- Wichita Family Medicine Specialists, LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 421
- Services billed
- 18,386
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,380 | 17 |
| Insertion of needle into vein for collection of blood sample | 818 | 394 |
| Established patient office or other outpatient visit, 20-29 minutes | 744 | 298 |
| Blood test, comprehensive group of blood chemicals | 691 | 384 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 576 | 365 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 478 | 83 |
| Blood test, lipids (cholesterol and triglycerides) | 466 | 351 |
| Blood test, thyroid stimulating hormone (tsh) | 408 | 332 |
| Established patient office or other outpatient visit, 30-39 minutes | 382 | 217 |
| Hemoglobin a1c level | 344 | 260 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 67 payments worth $945 in total to this clinician.
| Food and Beverage | $945 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $176,848 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc. - Study name not reported
Lexicon Pharmaceuticals, Inc. - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.